{
  "id": 2716913,
  "title": "Ascendis Pharma (ASND): Three New Drugs Are Turning This Biotech Into A Growth Machine",
  "url": "https://urgent.news/2026/08/21/ascendis-pharma-asnd-three-new-drugs-are-turning-this-biotech-into-a",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-21T21:46:40.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/healthcare/articles/ascendis-pharma-asnd-three-drugs-214640196.html"
  },
  "original_language": "en",
  "account": "Ascendis Pharma (ASND) has seen a surge in growth following the introduction of three new drugs. In their second-quarter report, the biotech company announced that total product revenue had nearly doubled to €315 million compared to the previous year. All three of the company's approved TransCon therapies – SKYTROFA, YORVIPATH, and YUVIWEL – began generating meaningful sales in the same quarter for the first time. YORVIPATH, a treatment for hypoparathyroidism, reached €252 million in the quarter and has become a blockbuster drug just two years after its U.S. launch. YUVIWEL, the newest addition, brought in €8 million in its first quarter on the market and has already enrolled more than 220 patients, with 65% already approved for reimbursement. The company's strong financial position, with €812 million in cash and no bank or convertible debt, allows it to fund these launches without external financing. Although reported operating profit included a €158 million gain from a previous sale, non-IFRS profit reached €92 million, reflecting a 27% margin. Despite this impressive growth, the company faces challenges such as rising costs and the uncertain regulatory timelines for YUVIWEL's full approval. The stock trades at a forward price-to-earnings ratio of 15.92, which may not be justified by the growth rate YORVIPATH and YUVIWEL are currently achieving.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}